Zoetis (ZTS) is under the microscope with evaluations of its
valuation in light of
Health Canada's approval of its new osteoarthritis therapy,
Lenivia. However,
Weiss Ratings maintains a
Hold (C-) rating. There is speculation of a
bull case theory while some
asset management firms reduce their holdings in Zoetis. Against this backdrop, anticipation builds around Zoetis beating
earnings estimates once again. The approvals for Lenivia could be the start of a new chapter in Zoetis'
innovation narrative. Following the
Dividend Announcement and
FDA nod for
Dectomax-CA1 Injectable, valuation reassessments continue. Despite a 22% slide in the past year, some argue Zoetis is worth watching. Lenivia approvals uniquely position Zoetis with promising innovation pipeline and recurring revenue outlook. The company has received a
positive opinion from CVMP for Portela®, which could expand its animal health portfolio. Amid market improvements, ZTS stock declines. However, Zoetis is considered a
Strong Growth and
Momentum Stock by some. Still, Zoetis is battling a larger drop than the general market.
Zoetis ZTS News Analytics from Thu, 29 May 2025 07:00:00 GMT to Sat, 25 Oct 2025 16:53:27 GMT -
Rating 1
- Innovation 4
- Information 5
- Rumor -4
